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doi:10.1016/j.seizure.2005.01.006Summary Studies of the efficacy of topiramate (TPM) in infants and young children
are few. Here we report an open, prospective, and pragmatic study of effectiveness of
TPM in terms of epilepsy syndromes, in children aged less than 2 years. The median
follow-up period was 11 months. We enrolled 59 children in the study: 22 affected by
localization-related epilepsy (LRE), 23 by generalized epilepsy, six by Dravet’s
syndrome, and eight with unclassifiable epilepsy. TPM was effective (responders
showed a decrease of more than 50% in seizure frequency) in 47% of patients,
including 13% who were seizure-free at the last visit. TPM was more effective in
localization-related epilepsy (48% of responders) than in generalized epilepsy (32% of
responders). In the latter group, 19 patients suffered from infantile spasms. Four of
six patients with cryptogenic infantile spasms became seizure-free. Of the 13 patients
with symptomatic infantile spasms, only one was seizure-free. Results were poor for
patients with Dravet’s syndrome. In general, TPM was well tolerated. The most
frequently reported adverse effects were drowsiness, irritability, hyperthermia,
and anorexia.
The present study concludes that TPM is effective for a broad range of seizures
in infants and young children and represents a valid therapeutic option in this
population.
# 2005 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.Introduction adults with partial and generalized tonic—clonicTopiramate (TPM) is an antiepileptic drug (AED) with
a broad range of antiseizure activities.1 Controlled
studies have demonstrated the efficacy of TPM in7586 522;
Balestri).
5 BEA Trading Ltd. Publishedseizures.1—3 In adult patients with newly diagnosed
epilepsy, TPM is at least as effective as therapeutic
doses of carbamazepine and valproate.4 TPM is
also effective in children affected by generalized
or partial refractory epilepsy,5 Lennox—Gastaut
syndrome,6,7 refractory infantile spasms,8,9 myoclo-
nic—astatic epilepsy,10 childhood absence sei-
zures,11 and as recently reported, in children with
refractory status epilepticus.12,13by Elsevier Ltd. All rights reserved.
184 S. Grosso et al.Here, we report on the efficacy of TPM as an add-
on drug in a series of children aged less than 2 years
affected by epilepsy.Patients and methods
In the period between January 1999 and October
2003, 59 children affected by epilepsy were enrolled
in the study: 28 girls and 31 boys, with ages ranging
from 1month to 24 months (mean 13  0.8 months).
The patients were recruited from our clinic and
were selected according to the following criteria:
(i) aged less than 2 years; and (ii) seizures refractory
to at least one AED. Family and personal histories
were recorded and neurological examinations
performed on all patients. Biochemical and chro-
mosomal investigations were carried out when con-
sidered necessary. Electroencephalograms (EEGs)
were recorded during wakefulness, spontaneous
sleep, and arousal. Long-term video EEG was per-
formed when considered useful in classifying the
type of epilepsy. All patients underwent imaging
studies with brain magnetic resonance imaging
(MRI). Single-photon emission computed tomogra-
phy (SPECT) or positron emission tomography (PET)
was also performed when considered necessary.
Seizure types and epilepsy syndromes were classi-
fied in accordance with the International League
Against Epilepsy (ILAE) classification of epileptic
seizures14 and epileptic syndromes.15,16 Etiology
was determined in 30 patients (51%) (Table 1).
Twenty-two patients (37%) were classified as having
localization-related epilepsy (LRE) (Table 2). The
two patients with idiopathic LRE (Table 2) were
affected by either early-onset occipital seizures
or benign partial epilepsy in infancy with seconda-
rily generalized seizures refractory to treatment
with carbamazepine. A patient affected by hot-
water epilepsy related to a left parietal cortical
dysplasia was also included in the group of patients
with symptomatic LRE. Ohtahara syndrome was
related to diffuse cortical dysplasia. CongenitalTable 1 Etiologic findings of patients.
Etiologies N
Symptomatic
Post-anoxia ischemia 16
Brain malformation 6
Chromosome anomalies 4
Post-infectious 2
Progressive metabolic disorders 2
Cryptogenic 27
Idiopathic 2cytomegalovirus infection was diagnosed in the
patient with myoclonic epilepsy and recurrent myo-
clonus status in non-progressive encephalopathy.17
Because TPM is not indicated for epileptic therapy in
children aged less than 2 years in Italy, informed
consent was obtained from the patients’ parents.
TPM was added to current treatments in an open
fashion. When TPM was added on therapy, all
patients were under treatment with a number of
AEDs ranging from one to three. In detail, 22
patients (37%) were receiving one AED, 24 patients
(41%) two AEDs, and 13 patients (22%) three AEDs.
Drugs administered at the outset of TPM therapy
included valproate (58%), carbamazepine (41%),
vigabatrin (37%), phenobarbital (24%), clonazepam
(22%), lamotrigine (7%), and chlormethyldiazepam
(5%). It is noteworthy that, on starting TPM, 68% of
patients (13/19) with infantile spasms were taking
vigabatrin only, whereas the remaining patients in
this group were treated with polytherapy. Moreover,
seven of these patients (37%) had already received
adrenocorticotropic hormone (ACTH) when they
first arrived under our care. TPM was administered
at a daily dose of 0.5—1.0 mg/kg, followed by a
week of titration in increments of 1—3 mg/kg, up
to amaximum of 10 mg/kg per day. If adverse events
occurred, the titration phase was prolonged on the
basis of the clinical condition. In patients with
infantile spasms, TPM titration was more rapid (over
a 7—10-day period) up to a dose 20—25 mg/kg per
day, according to the clinical response to the drug.
Mean seizure frequency was 43 per month (range 7—
68). The age at the onset of epilepsy ranged from 1
to 24 months (mean 9  2.5 months), and the time
interval from the onset of epilepsy to the beginning
of TPM treatment ranged from 1 to 11 months (mean
5  0.5 months). Efficacy was assessed according to
the epilepsy syndrome by parent seizure diaries.
Relative to the baseline seizure frequency and
severity, the response to TPM treatment was classi-
fied as follows: responders (reduction in seizures of
more than 50%); minimal (reduction in seizures of
less than 50%); unmodified (no change in fre-
quency); and worse (increase in seizure frequency
or seizure severity of at least 50%).
During treatment, general clinical and neurolo-
gical examinations were performed on all patients,
every month in patients with infantile spasms
and every 3 months in the remaining patients.
The presence of adverse events was obtained
from the parents at each control. Complete
peripheral blood counts, urinary analysis, blood
creatinine, and alanine and aspartate aminotrans-
ferase levels were also monitored, as were EEG
and, when possible, blood levels of concomitant
AEDs.
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Table 2 Efficacy of TPM according to epilepsy syndromes.
Epilepsy syndromes No. of patients Responders (seizure-free)
Localization-related epilepsy 22 14 (3)
Idiopathic
Early-onset occipital seizure 1 NR
Benign partial complex seizure 1 1 (0)
Cryptogenic 7 5 (1)
Symptomatic 12 7 (1)
Bathing epilepsy 1 1 (1)
Generalized 23 9 (5)
Cryptogenic
Infantile spasms 6 4 (4)
Symptomatic
Infantile spasms 13 4 (1)
Ohtahara syndrome 1 NR
Myoclonic epilepsy and MSNE 1 NR
Others 2 1 (0)
Dravet’s syndrome 6 2 (0)
Unclassifiable 8 3 (0)
MSNE: myoclonus status in non-progressive encephalopathy; NR: unresponsive.Statistical analysis
Proportions were compared using Fisher’s exact
test. Quantitative variables were compared using
Student’s t test or the two-tailed Wilcoxon rank sum
test.Results
The median follow-up period was 11 months (range
3—27 months; mean 14  6.4 months). Mean TPM
dose was 5.2 mg/kg per day (range 1.6—8.9 mg/kg
per day). In patients with infantile spasms, themean
TPM dose was 14.8 mg/kg per day (range 7.5—
21 mg/kg per day).
Efficacy
Twenty-eight patients (47%) were considered
responders because they presented with a reduction
of more than 50% in their seizure frequency. In the
remaining 31 patients, the drug treatment had been
tapered off because of inefficacy or the appearance
of adverse events. In detail, eight children (13%)
became seizure-free, 20 (34%) displayed a seizure
reduction of 50—99%, and 16 (28%) had a minimal
response. In a further 10 patients (17%), seizure
frequency remained unchanged, whereas five (8%)
experienced an increase in the frequency of sei-
zures. In seizure-free patients, the median follow-
up period was 7 months (range 4—16 months). With
respect to the type of epilepsy, TPM appeared moreeffective in LRE (48% of responders) than in general-
ized epilepsy (32% of responders), although the
difference was not statistically significant between
these two groups (P = 0.881 by Fisher’s exact test;
data not shown). With idiopathic LRE, the patient
with early-onset occipital seizures still had seizures
while treated with TPM, whereas the patient
affected by benign partial epilepsy of infancy with
secondarily generalized seizures was included
among the responders. TPM controlled seizures in
the latter patient, with the exception of those
triggered by fever, which were still occurring at
the last visit. Five of seven patients with crypto-
genic LRE were responsive to treatment, as were 7
of 12 patients with symptomatic LRE. Overall, in
three patients (one with cryptogenic and two with
symptomatic LRE) defined as ‘‘responders’’, febrile-
triggered seizures were still observed at the last
visit. The highest responder rates among patients
with generalized epilepsy were among those with
cryptogenic infantile spasms (four of six became
seizure-free), and two of these were placed on
TPM monotherapy. Of the 13 patients with sympto-
matic infantile spasms, only one was seizure-free
(7%) and another three were considered responders.
In the same group, there was a patient with Ohta-
hara syndrome and another affected by myoclonic
epilepsy with recurrent myoclonus status in non-
progressive encephalopathy, who were both unre-
sponsive to treatment.
Two responders (33%) were also observed among
the six patients with Dravet’s syndrome, and three
responders (9%) were observed among the patients
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increase or worsening of seizure frequency or sever-
ity was observed in two patients (9%) with sympto-
matic LRE and three (13%) with generalized epilepsy
(the latter patients were all affected by sympto-
matic infantile spasms).
Safety
Adverse events occurred in 22 patients (37% of the
total initial treatment group). In five patients, more
than one side effect occurred. The most frequently
reported treatment-related side effects were drow-
siness and nervousness,11 hyperthermia,11 and
weight loss (eight patients). Hyperthermia was
observed only during summer months. It was severe
(above 38.5 8C) in one patient, in whom rapid nor-
malization of body temperature was observed when
TPM treatments were tapered off. In 10 patients,
body temperature was mildly increased ranging
from 37.5 to, sporadically, 38 8C. In this group, side
effects were controlled by reducing the TPM dose.
For technical reasons, no patient underwent the
pilocarpine iontophoresis sweat test. However,
other possible causes of fever have been adequately
excluded. In two patients (one with cryptogenic LRE
and another with symptomatic LRE) who were
responsive to the drug, severe anorexia occurred
at a dose of 4 and 6.2 mg/kg per day, respectively.
Reducing these doses led to the disappearance of
the adverse effects, but an increase in seizure
frequency occurred in one of these patients. Slower
titration of the drug was therefore instituted, with
no appearance of side effects. Hemathological and
biochemical tests resulted normal in all patients.Discussion
Topiramate is currently approved in Italy for the
treatment of patients older than 2 years of age with
partial seizures and secondary generalized epilepsy,
as well as seizures associated with Lennox—Gastaut
syndrome. This paediatric open uncontrolled study
is one of the few attempts to evaluate the efficacy
of TPM in infants aged less than 2 years, in terms of
epilepsy syndromes. Although previous reports
seemed to suggest that TPM may be effective in
infants with epilepsy, very few cases have been
reported in the literature. About 55 were treated
for infantile spasms,9,18—22 less than 20 for Dravet’s
syndrome,21,23,24 and a number of patients were
treated for partial seizures.6,20,21,25 Furthermore,
the majority of these studies were performed to
evaluate TPM efficacy against specific seizure types.
Because the same type of seizure may be differentlyresponsive to an AED, depending on the epilepsy
syndrome for which it is prescribed, it is of cardinal
importance to evaluate the efficacy of an AED
according to epilepsy syndrome. This concept is
particularly true in paediatric populations, in
which a wide spectrum of epileptic syndromes is
observed.21,26
Several studies have established TPM efficacy in
partial seizures. A double-blind trial in partial-onset
seizures showed 39% of patients with seizure reduc-
tion of at least 50% and, in a long-term study, 14% of
patients were seizure-free, with 75% continuing on
TPM therapy.25 Many open trials involving children
with partial epilepsy confirmed the observations of
Elterman et al.2,5,27—29 In their open-label, prospec-
tive study, Mikaeloff et al.21 observed that among
patients with LRE, the percentage of responders was
higher (75%) among those aged less than 4 years,
prompting the authors to remark that young
patients tend to respond better to TPM therapy than
older ones. In the present study, we obtained similar
results, with 64% of responders among young
patients with LRE, confirming the effectiveness of
TPM in infants presenting with this type of epilepsy.
Globally, data available in the literature refer to the
efficacy of TPM in refractory or catastrophic partial
epilepsy. In contrast, the effects of TPM in more
benign forms of LRE in infancy remain to be estab-
lished.20 In this context, we found good responsive-
ness in a patient affected by benign partial epilepsy
of infancy with secondarily generalized seizures but
not in a patient with early-onset idiopathic occipital
epilepsy, who still experienced seizures at the last
visit.
Most available information on the effectiveness
of TPM in generalized epilepsy syndromes relates to
its role in infantile spasms, for which TPM was found
to be useful. In a pilot study involving 11 patients
subjected to TPM treatment, seven were still sei-
zure-free after 18 months.8,9 In a retrospective
study, four of seven patients with refractory infan-
tile spasms were also seizure-free.18 Herranz
reported his experience with open-label TPM use
in 13 patients with West syndrome. Nine infants
received TPM as the first-line drug, at a maximum
dose of 16 mg/kg per day. Two patients became
seizure-free and seven were defined as respon-
ders.22 Watemberg et al. reported that TPM was
able to reduce seizures in seven of eight patients
with refractory infantile spasms and, in three of
these, TPM monotherapy was undertaken.20 In con-
trast, negligible TPM efficacy was achieved by
Mikaeloff et al. in a sample of 14 patients with
infantile spasms, none of whom became seizure-
free.21 Nineteen patients affected by infantile
spasms were included in our series. The therapeutic
Epilepsy syndromes 187protocol we adopted in our institute included the
use of vigabatrin as the first-line drug. When total
control of seizures, which is the required response in
this particular type of epilepsy syndrome,30 was not
achieved, rapid titration of TPM up to 20—25 mg/kg
per day was attempted, when lower doses produced
a significant reduction in seizure frequency. Thera-
pies with ACTH, valproate, and clonazepam are
usually instituted subsequently. Four of six patients
with cryptogenic infantile spasms were seizure-free
after a median follow-up period of 14 months, and
two of these were placed on TPM monotherapy. On
the other hand, only 1 of 13 patients with secondary
infantile spasms became seizure-free. When
patients with cryptogenic infantile spasms are con-
sidered, the results observed in the present series
are consistent with those of Glausers8,9 and Thijs.18
In contrast, the poor results obtained for sympto-
matic infantile spasms are in line with those
observed in the study of Mikaeloff et al.21 TPM
was also unable to control seizures in two patients
affected by Ohtahara syndrome or myoclonic epi-
lepsy with recurrent myoclonic status in non-pro-
gressive encephalopathy.
In other types of epilepsy syndromes, such as
Dravet’s syndrome (severe myoclonic epilepsy of
infancy), TPM was also effective in that significant
seizure reduction was reported in 55% of patients,
including 15% of patients who became seizure-
free.23,24 In contrast, we had poorer results; only
two patients (33%) were responders and in neither
was complete control of seizures achieved.
Six patients displayed both febrile and afebrile
seizures in their epileptic profiles. Two patients
were unresponsive to TFM treatment. In the four
responsive patients, all affected by LRE, TPM was
unable to control those seizures triggered by febrile
illnesses. Few data are available in the literature on
this point. Our observations seem to indicate neg-
ligible efficacy of TPM in controlling febrile-trig-
gered seizures, at least in the present series of
patients.
With respect to tolerability, it is well known that
the side effects of TPM treatment are mainly repre-
sented by behavioural and cognitive difficulties,
with an incidence of almost 50% in one retrospective
review of 174 adult patients.31 In contrast, double-
blind studies in children recorded weight loss and
sedation as the most common complaints.6,25 In
open studies, adverse events were observed in
25% of children.24 Weight loss was reported to occur
at variable frequencies, ranging from 6%32 to around
40%.33,34 Reversible language regression was also
recently reported.35 Mikaeloff et al. found that
TPM was generally better tolerated in younger than
in older children.21 In the present study, adverseevents occurred at a rate of 37% and mainly pre-
sented as drowsiness, irritability, anorexia, weight
loss, and hypohydrosis. This led to discontinuation of
the drug in three patients. In general, adverse
events were mild in severity and were often
resolved by slowing the rate of TPM titration or
reducing the daily dose of the drug. Of course, it
was very difficult to evaluate side effects such as
sedation and slow thinking, reported to occur in
patients treated with TPM, because of the age of
the patients, most of who had psychomotor retar-
dation. Gastrointestinal effects, reported in pre-
vious studies,36 were not observed in the present
series. Moreover, no ophthalmological side effects
were observed, such as acute angle-closure glau-
coma, myopia, retinal striae, and uveitis,31,37
although no systematic instrumental investigations
were performed. In 58% of patients, TPM was admi-
nistered in association with valproate. Several
hematochemical investigations detected no side
effects resulting from such a combination, as have
been described elsewhere.19,38 With respect to
hypohydrosis and related hyperthermia, recent
reports have shown that up to 65% of patients sub-
jected to TPM therapy had a reduced quantity of
sweat in the pilocarpine iontophoresis sweat test.
However, only a minority of them was aware of heat
intolerance.39—41 We believe that is very difficult to
establish exactly the frequency of such an adverse
event because it is directly related to the environ-
mental temperature. Of course, owing to the age of
our patients, it was very difficult to evaluate pos-
sible heat intolerance. However, hyperthermia was
observed in 11 patients (18%). It was exclusively
observed during summer months (especially in sum-
mer 2003, when temperatures were very high in
Italy). In only one patient was hyperthermia so
severe that it prompted us to taper off therapy.
In the remaining group of patients, body tempera-
ture was mildly increased ranging from 37.5 8C to,
sporadically, 38 8C. It reversed to normal values
after the dose of TPM was reduced.
In conclusion, the present open, prospective,
and pragmatic study confirms that TPM is effective
across a broad range of seizure types in children
aged less than 2 years. Moreover, our data clearly
indicate the usefulness of TPM in cryptogenic
infantile spasms. In contrast, poor efficacy was
observed in symptomatic infantile spasms and in
Dravet’s syndrome. Good responsiveness was
observed in refractory LRE. TPM appears to be a
relatively well-tolerated drug and a slow progres-
sive titration helps to reduce adverse effects.
Therefore, TPM should be considered a valid ther-
apeutic option in infants and young children
affected by epilepsy.
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